WuXi STA and Coherent Biopharma have signed a strategic partnership agreement today. According to the agreement, WuXi STA will become the preferred CDMO partner and provide Coherent Biopharma with integrated CMC services to accelerate its present and future drug candidates (small molecule, peptide, oligonucleotide and complex chemical conjugate, etc.), from API to drug product, including, but not limited to the process development, manufacturing, analytical and regulatory filing support.
Based on the prior successful collaboration on CBP-1008, this strategic partnership between Coherent Biopharma and WuXi STA is to broaden the collaboration beyond CBP-1008. PDC drugs has broad applications, but the development faces many technical challenges. WuXi STA has been deeply involved in the CDMO industry for more than twenty years, with its leading capability and capacity for small molecule, peptide, high-potency API and complex conjugate such as PDC. It will provide a strong support for Coherent Biopharma PDC drug candidate development.
Speaking in this regard, Dr Baohua Huang, Chair and GM, Coherent Biopharma, commented, “We are happy to enhance our partnership with WuXi STA to the next level, who is well-known for its world-class scientific and technical strengths and industry-leading end-to-end services, which offer great support to our PDC drugs. I am confident that our cooperation will accelerate the pathway of our cancer drugs to market for the benefit of global patients.”
Adding to it, Dr Minzhang Chen, Co-CEO, WuXi AppTec and CEO, WuXi STA, also said, “We are pleased to form a strategic partnership with Coherent Biopharma. Coherent is one of the pioneers in the development of PDC drugs in China and has made great progress. We are looking forward to further leveraging our proven integrated CMC platform, along with our global standard quality systems, to accelerate Coherent’s innovative drug development and ultimately benefit global patients.”